Ashley Chan

Ashley Chan joined the OncLive team as an assistant editor in 2025 after previously working on the CURE editorial team since 2023.

Email: achan@mjhlifesciences.com

Articles

Real-World Data Support the Frontline Use of Avelumab Plus Axitinib in Advanced RCC

February 15th 2025

The combination of first-line avelumab and axitinib was effective and safe in a real-world analysis of patients with advanced RCC.

Obe-Cel Elicits High MRD-Negative Response Rates in R/R B-ALL

February 14th 2025

MRD-negative remissions with obe-cel were more durable and associated with higher EFS and OS rates vs MRD-positive remissions in relapsed/refractory B-ALL.

UGN-102 Induces Clinically Meaningful CR Rates in Low-Grade, Intermediate-Risk NMIBC

February 14th 2025

UGN-102 generated robust, durable responses in patients with low-grade, intermediate-risk NMIBC, in analyses of the phase 3 ENVISION and ATLAS studies.

Olaparib Plus Abiraterone Improves Radiographic PFS and OS in BRCA+ mCRPC

February 14th 2025

First-line therapy with olaparib plus abiraterone demonstrated clinical benefit in rPFS and OS in mCRPC harboring germline and somatic BRCA mutations.

Potential Applications of Cancer Vaccines Continue to Expand in Squamous Cell Carcinoma

February 12th 2025

Omid Hamid, MD, discusses therapies emerging in the squamous cell carcinoma treatment paradigm, including a novel cancer vaccine.

Precise Targets and Drug Sequencing Potential Characterize the State of ADCs in Ovarian Cancer

February 11th 2025

Kathleen N. Moore, MD, MS, discusses ongoing trials of novel ADCs in ovarian cancer and the potential relevance of biomarker expression for these agents.

Pola-R-CHP Generates Long-Term PFS and DFS Advantages vs R-CHOP in Untreated DLBCL

February 7th 2025

Polatuzumab vedotin plus R-CHP improved PFS and DFS vs R-CHOP at 5 years in previously untreated patients with diffuse large B-cell lymphoma.

Venetoclax Elicits Immune Synapse Repair in Chronic Lymphocytic Leukemia

February 7th 2025

Matthew Cortese, MD, MPH, discusses an evaluation of immunologic changes with the treatment of venetoclax in patients with chronic lymphocytic leukemia.

ATG-022 Demonstrates Safety, Preliminary Efficacy in Advanced CLDN18.2+ Gastric Cancer

February 6th 2025

Phase 1 study data demonstrated that ATG-022 has a manageable safety profile and produced activity in patients with gastric cancer and CLDN 18.2 expressions.

Ziftomenib Meets CR/CRh End Point in R/R NPM1+ AML

February 6th 2025

The oral menin inhibitor ziftomenib produced responses in patients with relapsed/refractory NPM1-mutant AML.

FDA Grants Orphan Drug Designation to 225Ac-Satoreotide for SCLC

February 6th 2025

The FDA has granted orphan drug designation to 225Ac-satoreotide for patients with small cell lung cancer.

Type II JAK Inhibitor AJ1-11095 Under Phase 1 Investigation in Myelofibrosis

February 5th 2025

AJ1-11095 is being evaluated in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia.

Rovadicitinib Shows Safety, Clinical Activity After Ruxolitinib Intolerance in Myelofibrosis

February 5th 2025

The JAK/ROCK inhibitor rovadicitinib may provide a safe and effective new treatment option for patients with myelofibrosis who progressed on ruxolitinib.

Axi-Cel Shows Durable Responses, May Have Curative Potential in R/R Indolent Non-Hodgkin Lymphoma

February 4th 2025

Sattava S. Neelapu, MD, discusses updated data from the 5-year follow-up analysis evaluating axi-cel in relapsed/refractory indolent non-Hodgkin lymphoma.

Emavusertib Holds Potential for Combination Therapies in AML/MDS

February 4th 2025

Guillermo Garcia-Manero, MD, discusses the developmental progress of emavusertib for the treatment of acute myeloid leukemia and myelodysplastic syndromes.

Targeted Therapies for NSCLC With Nonclassical EGFR Mutations Grow Increasingly Personalized

February 4th 2025

The variety of nonclassical EGFR mutations in NSCLC necessitates the development of unique treatment strategies based on individual mutational profiles.

TAK-007 Shows Favorable Safety, Early Efficacy Data in R/R B-Cell Non-Hodgkin Lymphoma

February 4th 2025

A phase 2 study demonstrated that TAK-007 had a favorable safety profile with early efficacy in relapsed/refractory B-cell non-Hodgkin lymphoma.

Trend Towards Favorable DFS Observed With Cisplatin/Paclitaxel in HRD Advanced Ovarian Cancer

January 31st 2025

Cisplatin/paclitaxel showed trend towards improved DFS vs cisplatin alone in advanced-stage ovarian cancer.

Observational Data Challenge p53 Expression as a Surrogate Marker for TP53 Mutations in High-Risk Endometrial Cancer

January 30th 2025

An observational cohort study determined that discordance exists between p53 protein expression and TP53 mutation status in high-risk endometrial cancer.

European Commission Approves Blinatumomab Consolidation in Newly Diagnosed CD19+ B-ALL

January 30th 2025

The European Commission has approved blinatumomab as consolidation therapy for Ph-negative, CD19-postive B-cell precursor acute lymphoblastic leukemia.